硼替佐米治疗多发性骨髓瘤的临床疗效

Clinical effect of bortezomib in the treatment of multiple myeloma

目的探讨硼替佐米治疗多发性骨髓瘤的临床疗效。方法选取漳州市医院2013年6月—2014年11月收治的多发性骨髓瘤患者40例,随机分为对照组和观察组,各20例。对照组患者给予常规化疗方案,观察组患者在对照组基础上采用予硼替佐米治疗。比较两组患者的临床疗效、2年生存率及毒副作用发生情况。结果两组患者疾病控制率(DCR)、客观缓解率(ORR)比较,差异无统计学意义(P>0.05)。观察组2年生存率高于对照组(P<0.05)。两组患者均未发生严重毒副作用。结论硼替佐米治疗多发性骨髓瘤的临床疗效确切,可提高患者生存期,且安全性较高。

Objective To investigate the clinical effect of bortezomib in the treatment of multiple myeloma.Methods A total of 40 cases of multiple myeloma patients were selected from June 2013 to November 2014 in Zhangzhou Hospital,which were randomly divided into control group and observation group,20 cases in each group.The control group were given routine chemotherapy,while the observation group were given bortezomib based on control group.The clinical effect,2-year survival rate and the occurrence of toxic and side effects were compared between the two groups.Results There was no significant differences of disease control rate(DCR)or objective remission rate(ORR)between the two groups(P>0.05).The 2-year survival rate in observation group was higher than control group(P<0.05).There were no serious side effects between the two groups.Conclusion Bortezomib is effective in the treatment of multiple myeloma,which can improve the survival time,and with high safety.